GLIOBLASTOMA
Extended Research Project by Mounami Reddy Kayitha
Aragon High School, 2022
Glioblastoma multiforme (GBM) is the most malignant of brain tumors, classified as a grade IV glioma that originates in glial tissue. GBMs have a low median survival rate of 15 months, despite surgery and treatment with a chemotherapy drug. The reasons for this low overall survival rate is because of GBM heterogeneity and differing mutational profiles within the tumor itself. Therefore, mutation-specific drugs that would impact the entirety of the GBM tumor are difficult to develop. However, other ventures, including driver mutation-focused drugs, neuroimaging, and immunotherapy could provide treatment against glioblastomas. As a result, recent research focuses on the understanding and treatment of glioblastomas will be explored further as a primary focus in this blog.
Tissue Samples of Glioblastoma
My Prior Knowledge
Oncology
Hallmarks of cancer
genetic mutations
EGFR
Neurology
Brain anatomy
Memory (short term, long term, working, potentiation)
Learning
Current Research Goals
Understand Genetics and pathology of GBM
Driver mutations
Treatment methods for GBM
Mutation-specific treatments
Latest research on GBM
Extended research (ER) done as a part of Neuroscience Program at Elio Academy of Biomedical Sciences
Review Paper
Glioblastoma multiforme.docxPoster
Mutations-IDH1-MGMT-Glioblastoma.pdf